Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.
Data for acute respiratory diseases showed an upward trend in overall infections in the week of Dec. 16 to 22, according to an official statement released on Thursday. China is likely to be ...
MP-1032 is under clinical development by MetrioPharm and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase I drugs for Inflammatory Bowel Disease have a 73% phase ...